BeiGene

beigene.com

BeiGene is a global biotechnology company focused on discovering and developing innovative oncology treatments. The company aims to make its medicines more accessible and affordable to cancer patients worldwide, leveraging a large team of over 11,000 employees and a significant oncology research portfolio. BeiGene's key products include the BTK inhibitor BRUKINSA®, approved in over 65 markets, and tislelizumab, which is under regulatory review in the U.S. and EU. With a robust pipeline addressing 80% of cancer types by incidence, BeiGene is positioned as a leader in the oncology space, committed to improving patient outcomes through persistent innovation and global reach.